Search results for Gevokizumab

Gevokizumab Biosimilar – Anti-IL1B mAb – Research Grade, ProteoGenix, PX-TA1068

Description of Gevokizumab Biosimilar - Anti-IL1B mAb - Research Grade Introduction Gevokizumab Biosimilar, also known as Anti-IL1B mAb, is a research grade monoclonal antibody that targets the cytokine interleukin-1 beta (IL-1B). This antibody has shown promising results in clinical trials for the treatment of inflammatory diseases and is currently being developed as a biosimilar to the original drug, gevokizumab. Structure of Gevokizumab Biosimilar Gevokizumab Biosimilar is a humanized monoclonal antibody, meaning it is derived from both human and mouse sources. It consists of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. These chains are linked by disulfide bonds and form a Y-shaped structure. The variable regions of the antibody, located at the tips of the Y, are responsible for binding to IL-1B. The constant regions, located at the base of the Y, are responsible for mediating effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Mechanism of Action IL-1B is a pro-inflammatory cytokine that plays a key role in the pathogenesis of many diseases, including rheumatoid arthritis, gout, and type 2 diabetes. Gevokizumab Biosimilar works by binding to IL-1B and preventing it from interacting with its receptors on target cells. By blocking the activity of IL-1B, Gevokizumab Biosimilar reduces inflammation and associated symptoms such as pain and swelling. It also helps to regulate the immune response and promote tissue repair. Applications of Gevokizumab Biosimilar Gevokizumab Biosimilar has shown promising results in clinical trials for the treatment of various inflammatory diseases. It has been studied in patients with rheumatoid arthritis, psoriasis, and gout, among others. One of the key advantages of this biosimilar is its potential to offer a more cost-effective alternative to the original drug, gevokizumab. This could make it more accessible to patients in need of treatment for these debilitating diseases. Research Grade vs. Therapeutic Grade Gevokizumab Biosimilar is currently being developed as a research grade antibody, meaning it is intended for use in laboratory research and not for human therapeutic purposes. However, it is important to note that the same antibody can be used for both research and therapeutic purposes, as long as it meets the necessary quality and safety standards. In order for Gevokizumab Biosimilar to be approved for therapeutic use, it will need to undergo further clinical trials and meet stringent regulatory requirements. This process can take several years, but if successful, the biosimilar could potentially provide a more affordable treatment option for patients. Conclusion Gevokizumab Biosimilar, also known as Anti-IL1B mAb, is a research grade monoclonal antibody that targets the pro-inflammatory cytokine IL-1B. It has shown promising results in clinical trials for the treatment of inflammatory diseases and is being developed as a biosimilar to the original drug, gevokizumab. Its unique structure and mechanism of action make it a promising candidate for the treatment of various inflammatory conditions. Further research and development will be necessary before it can be approved for therapeutic use, but if successful, it could offer a more cost-effective treatment option for patients in need.

Gevokizumab, Abbexa, abx831034

Gevokizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL1B, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Gevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine imbalance in IL-1 mediated disease states. It has a very high binding affinity of 300fM and blocks the activation of IL-1 receptors.

Gevokizumab ELISA Kit, ProteoGenix, KPTX132

Description of Gevokizumab ELISA Kit Gevokizumab ELISA Kit: A Powerful Tool for Detecting and Studying Therapeutic Antibody Gevokizumab ELISA Kit: A Scientific Overview The Gevokizumab ELISA Kit is a highly sensitive and specific tool used for the detection and quantification of the therapeutic antibody, Gevokizumab, in various biological samples. This kit is designed to provide researchers with a reliable and efficient method for studying the structure, activity, and application of this important therapeutic target. Structure of Gevokizumab Gevokizumab is a humanized monoclonal antibody that targets interleukin-1 beta (IL-1β), a pro-inflammatory cytokine involved in various inflammatory diseases such as rheumatoid arthritis, psoriasis, and type 2 diabetes. The antibody is composed of two heavy chains and two light chains, and has a molecular weight of approximately 150 kDa. Principle of Gevokizumab ELISA Kit The Gevokizumab ELISA Kit is based on the principle of enzyme-linked immunosorbent assay (ELISA), a widely used technique for the detection and quantification of specific proteins in biological samples. This kit utilizes a sandwich ELISA format, where the antibody-coated plate captures the target antigen (Gevokizumab) present in the sample. The captured antibody is then detected by a secondary enzyme-labeled antibody, and the signal is amplified by the addition of a substrate, resulting in a measurable color change. Activity of Gevokizumab Gevokizumab is a potent inhibitor of IL-1β, which plays a crucial role in the inflammatory response. By binding to IL-1β, Gevokizumab prevents its interaction with its receptor and subsequent downstream signaling, thus reducing inflammation and associated symptoms. This activity has been demonstrated in various preclinical and clinical studies, making Gevokizumab a promising therapeutic target for inflammatory diseases. Application of Gevokizumab ELISA Kit The Gevokizumab ELISA Kit has a wide range of applications in the field of drug development and research. It can be used to measure the concentration of Gevokizumab in various biological samples, such as serum, plasma, and cell culture supernatant, providing valuable information on drug pharmacokinetics and pharmacodynamics. This kit can also be used to screen and select high-affinity Gevokizumab clones during antibody development, as well as to monitor the stability and quality of Gevokizumab during manufacturing and storage. Conclusion The Gevokizumab ELISA Kit is a powerful tool for detecting and studying the therapeutic antibody, Gevokizumab. Its high sensitivity and specificity, along with its easy-to-use format, make it an essential kit for researchers working on Gevokizumab and IL-1β-related diseases. With the increasing interest in Gevokizumab as a potential treatment for various inflammatory conditions, this kit will continue to play a crucial role in advancing drug development and research in this field.

Gevokizumab ELISA Kit, Abbexa, abx395021

Gevokizumab ELISA Kit is a quantitative ELISA kit for detection of Gevokizumab.Gevokizumab (XOMA-052) was developed by XOMA Ltd., USA and represents a humanized IgG2 kappa antibody. XOMA-052 binds to IL-1β with high affinity leading to reduced binding affinity of the cytokine to its signaling receptor. Since gevokizumab does not influence the affinity of IL-1β for its decoy and soluble inhibitory receptors the endogenous regulatory mechanisms involving the clearance and inhibitory receptors also contribute to the effect of the antibody [6]. In August 2012 the FDA granted orphan drug status to gevokizumab for the treatment of noninfectious intermediate uveitis, posterior uveitis, panuveitis, and chronic noninfectious anterior uveitis. A single intravenous injection of the substance was also shown to lead to complete resolution of intraocular inflammation in Behçet’s uveitis.

Gevokizumab Biosimilar - Research Grade, ichor.bio, ICH5133

Detects human IL-1B

Research Grade Gevokizumab (HF943026), abinScience, HF943026